Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs

AAPS Journal

Volumn 8, Issue 4, 2006, Pages

  Thomas, Brian F ^a   Zhang, Yanan ^a   Brackeen, Marcus ^a   Page, Kevin M ^a   Mascarella, S Wayne ^a   Seltzman, Herbert H ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

Antagonists; Cannabinoid receptor; CB1; Conformational analysis; Molecular modeling; SR 141716A; Structure activity relationships

Indexed keywords

ACCOMPLIA; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; NESS 0327; PYRAZOLE DERIVATIVE; RIMONABANT; RIMONABANT DERIVATIVE; SR 171716A; UNCLASSIFIED DRUG; PIPERIDINE DERIVATIVE;

BINDING AFFINITY; CIS TRANS ISOMERISM; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; OBESITY; PATENT; RECEPTOR AFFINITY; SHORT SURVEY; SMOKING CESSATION; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; TOBACCO DEPENDENCE; X RAY CRYSTALLOGRAPHY; ARTICLE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; DRUG INTERACTION; METABOLISM; PHYSIOLOGY;

DRUG INTERACTIONS; MOLECULAR CONFORMATION; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1;

EID: 33947604827     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080476     Document Type: Short Survey

References (15)

1. Cleland JG, Ghosh J, Freemantle N, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004;6:501-508.
2. Muccioli GG, Lambert DM. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr Med Chem. 2005;12:1361-1394.
3. Padgett LW. Recent developments in cannabinoid ligands. Life Sci. 2005;77:1767-1798.
4. Lange JH, Kruse CG. Keynote review: medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today. 2005;10:693-702.
5. Hurst DP, Lynch DL, Barnett-Norris J, et al. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H- pyrazole-3 carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol. 2001;62:1274-1287.
6. Francisco ME, Seltzman HH, Gilliam AF, et al. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). J Med Chem. 2002;45:2708-2719.
7. Carpino PA, Griffith DA, Sakya S, et al. New bicyclic cannabinoid receptor-1 (CB(1)-R) antagonists. Bioorg Med Chem Lett. 2006;16:731-736.
8. Rinaldi-Carmona M, Barth F, Millan J, et al. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284:644-650.
9. Wiley JL, Jefferson RG, Grier MC, Mahadevan A, Razdan RK, Martin BR. Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation. J Pharmacol Exp Ther. 2001;296:1013-1022.
10. Thomas BF, Francisco ME, Seltzman HH, et al. Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)4-methyl-1Hpyra zole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. Bioorg Med Chem. 2005;13:5463-5474.
11. Mussinu JM, Ruiu S, Mule AC, et al. Tricyclic pyrazoles. 1. Synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2c] pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem. 2003;11:251-263.
12. Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR. SR-141716A-induced stimulation of locomotor activity: a structure-activity relationship study. Pharmacol Biochem Behav. 2002;74:31-40.
13. Stoit AR, Lange JH, Hartog AP, et al. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem Pharm Bull (Tokyo). 2002;50:1109-1113.
14. Murineddu G, Ruiu S, Loriga G, et al. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1, 4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J Med Chem. 2005;48:7351-7362.
15. Murineddu G, Ruiu, S, Mussinu JM, et al. Tricyclic pyrazoles. 2. Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. Bioorg Med Chem. 2005;13:3309-3320.